Wealth Fund Had Invested in Series B for Emerging Pharma Company

Sovereign wealth funds continue to play a key part in the aggregate investor composition in emerging pharmaceutical companies in the United States, especially in the areas of cancer therapies and combating neurodegenerative diseases. [ Content protected for Sovereign Wealth Fund Institute Standard subscribers only. Please subscribe to view content. ]


Contact the writer or creator of this article or page.
Questions or comments: support(at)swfinstitute(dot)org
Follow on Twitter at @swfinstitute and @sovereignfunds
Learn, Attend and Network: Institutional Investor Events and Summits
Go Back: HOME: Sovereign Wealth Fund Institute
 
institutional investor investment mandates